Drew Taylor is the Co-Founder and CEO of Acorn Biolabs.
Acorn has developed the world’s first non-invasive, follicle-based cell cryopreservation service and has patented cell-based treatments made from a patient’s own hair follicle cells.
Takeaways
Moving from playing MLB baseball to doing his PhD.
Regenerative medicine is needed to address the limitations of prosthetics and improve patient outcomes.
Banking younger cells can provide better results in regenerative medicine and enhance healthspan.
The field of regenerative medicine is gaining momentum, with a focus on anti-aging, longevity, and healthspan.
Raising capital in the regenerative medicine space can be challenging due to the complexity of the field and the need to find investors who understand both the medical and business aspects.
Acorn's banking service involves specialized facilities for processing and storing cells, leveraging existing infrastructure, and ensuring safety and maintenance.
The future of regenerative medicine includes making the storage of younger cells a standard of care and leveraging stem cells for maintenance and performance as individuals age.
Chapters
00:00 Transition from Baseball to PhD
01:35 Lessons from Baseball for Founding a Company
07:06 Identifying the Need for Regenerative Medicine
09:25 The Importance of Collecting Younger Cells
12:17 Driving Factors in the Regenerative Medicine Space
20:17 Team Composition at Acorn
23:38 Raising Capital in the Regenerative Medicine Space
28:03 Acorn's Banking Service and Expansion
30:57 The Future of Acorn and Regenerative Medicine
35:21 Dealing with Hard Times
37:02 Engaging with Regenerative Medicine
